Loading stock data…
Enovis Corporation (ENOV)
$19.98+1.42 (+7.65%)
Market ClosedLast close Sep 8
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enovis Corporation in the Healthcare sector is trading at $19.98 with a market capitalization of $1.1B. Wall Street consensus targets $38.33 (12 analysts), implying a +91.9% move over the next 12 months. The stock is currently near its 52-week low of $18.52, remaining 19.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +91.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $582.78M↓ | $589.15M↑ | $575.76M↑ | $548.91M↓ | $564.54M |
| Gross Profit | $359.25M↓ | $365.49M↑ | $349.42M↑ | $328.91M↓ | $334.70M |
| Operating Income | $22.27M↑ | $9.24M↓ | $48.25M↑ | -$8.14M↑ | -$16.08M |
| Net Income | -$1.19M↑ | -$8.76M↑ | -$520.59M↑ | -$571.15M↓ | -$36.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-74.59%
Volume
Today's trading volume
3.74M
Recent News
Q2 Earnings Highlights: Enovis (NYSE:ENOV) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Enovis (NYSE:ENOV) and its peers.
Enovis (ENOV) Stock Fair Value Falls As Analysts Weigh Robotics And Margin Pressure
Enovis is back in focus for investors after a modest reset in its implied price target, with fair value in one model shifting from US$42.30 to about US$38.33. Analysts link this move to fresh thinking on the eCential Robotics acquisition, recent free cash flow trends, and the latest Q2 read through to growth plans and execution risk. As you read on, you will see how these moving parts shape the evolving Enovis story and what to watch next in the analyst narrative. Stay updated as the Fair...
What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.